Zynex welcomes new CEO and leadership team to drive future growth

ENGLEWOOD, Colo. - Zynex, Inc. (NASDAQ:ZYXI) announced Monday that Steven Dyson has officially started his role as CEO alongside several new executive appointments as the medical technology company reshapes its leadership team. The leadership changes come at a challenging time for Zynex, which according to InvestingPro data, has seen its stock decline over 80% in the past year and faces significant operational headwinds.

The company has named Vikram Bajaj as Chief Financial Officer, John T. Bibb as Chief Legal Officer, Ajay Gopal as Executive Vice President of Sales, and Agnes Powell as Vice President of Billing. All new leaders began their roles on August 18.

Bajaj brings over 20 years of finance leadership experience in the med-tech sector, previously serving as CFO at Vyaire Medical and Kepro. Bibb joins with more than two decades of legal, compliance and HR experience in medical technology companies. Gopal has held commercial leadership positions at KCI, Danaher, and Healthium Medtech, while Powell contributes 20 years of experience in healthcare revenue cycle operations.

Dyson’s executive leadership team will include Bajaj and Bibb along with Anna Lucsok, the company’s COO, and Donald Gregg, President of Zynex Monitoring Solutions.

"I am very pleased that we have been able to move quickly to fill critical roles at the Company as we begin to create a new future for all Zynex stakeholders," Dyson said in the press release.

Thomas Sandgaard, founder and Chairman of the Board, expressed confidence in the new leadership team’s ability to advance the company’s growth.

Zynex, founded in 1996, manufactures and sells non-invasive medical devices for pain management, rehabilitation, and patient monitoring.

In other recent news, Zynex announced a significant leadership change with the appointment of Steven Dyson as the new Chief Executive Officer, effective August 18, 2025. Dyson, who has over 25 years of experience in the medical technology sector, joins from the global private equity firm Apax. Additionally, Chief Financial Officer Dan Moorhead has decided to resign, effective August 29, 2025, and will enter a consulting agreement to assist with the transition. In financial developments, Zynex faced a first-quarter revenue miss, leading RBC Capital to lower its price target for the company from $4.00 to $3.00, while maintaining a Sector Perform rating. This decision was influenced by Zynex’s choice not to issue guidance for 2025, adding to the uncertainty surrounding its financial outlook. Meanwhile, Tricare, Zynex’s largest insurance customer, has extended its temporary payment suspension amid an ongoing review. Despite these challenges, H.C. Wainwright has reiterated a Buy rating on Zynex stock, maintaining an $8.00 price target. These developments highlight the significant changes and challenges currently facing Zynex.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.